Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TCH346 · 4 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| TCH346 | DRUG | - |
| TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt) | DRUG | - |
Inclusion Criteria: * Completed original protocol, Study No. CTCH346A2211 * Be capable of satisfying the requirements of the extension protocol and must sign informed consent after the nature of the extension protocol has been fully explained Exclusion Criteria: * Exclusion criteria as described ...
TCH346 is an investigational small molecule developed by Novartis AG for neurological conditions. It was studied in amyotrophic lateral sclerosis (ALS) and Parkinson's disease. It is also known as dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt. All of its clinical trials have been completed, and no trials are currently active.
TCH346 was studied for the treatment of amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Its clinical program included three completed trials in ALS and one completed trial in early Parkinson's disease. It is an investigational agent and is not described as an approved therapy for either indication.
TCH346 was developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the clinical trial program evaluating the drug in amyotrophic lateral sclerosis and Parkinson's disease.
TCH346 reached Phase 2 clinical development. Its trials include Phase 2 studies in amyotrophic lateral sclerosis and a Phase 1 study in early Parkinson's disease. All of these trials are completed, and no TCH346 trials are currently active.
TCH346 was evaluated in completed trials including NCT00072709 and NCT00230074 in amyotrophic lateral sclerosis, NCT00036413, a 12-week safety and dose-ranging study in ALS, and NCT00407212, a study of three doses in early Parkinson's disease. These trials enrolled a combined total of 945 participants.